• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by MDxHealth SA

    10/4/24 5:14:19 PM ET
    $MDXH
    Medical Specialities
    Health Care
    Get the next $MDXH alert in real time by email
    SC 13G 1 mdxh13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    MDxHealth SA

    (Name of Issuer)

     

     

    Ordinary Shares

    (Title of Class of Securities)

     

     

    B5950S113

    (CUSIP Number)

     

     

    September 26, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. B5950S113

     

    1.Names of Reporting Persons.

    Laurence W. Lytton

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization USA

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 2,889,595

     

    6. Shared Voting Power 1,000

     

    7. Sole Dispositive Power 2,889,595
    8. Shared Dispositive Power 1,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,890,595

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.1%

     

    12.Type of Reporting Person (See Instructions) IN

     

     2 
    CUSIP No. B5950S113

    Item 1.

     

    (a)Name of Issuer

    MDxHealth SA

     

    (b)Address of Issuer's Principal Executive Offices

    CAP Business Center, Zone Industrielle des Hauts-Sarts, 4040 Herstal, Belgium

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Laurence W. Lytton

    (b)The principal business office of the Filers is located at:

    467 Central Park West
    New York, NY 10025

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to Ordinary Shares of the Issuer (the "Stock").

     

    (e)The CUSIP number of the Issuer is: B5950S113
     3 
    CUSIP No. B5950S113
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page.

     

    The percentages reported in this Schedule 13G are based on 47,288,093 Ordinary Shares outstanding as after the completion of the offering reported in the Prospectus Supplement filed by the Issuer on September 26, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 4, 2024

     

     

    /s/ Laurence W. Lytton

    Laurence W. Lytton

     

     

     

    Get the next $MDXH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MDXH

    DatePrice TargetRatingAnalyst
    10/31/2024$7.00Buy
    Lake Street
    5/31/2023$7.00Outperform
    TD Cowen
    7/18/2022$18.00Outperform
    Oppenheimer
    More analyst ratings

    $MDXH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Mvm Partners, Llc bought $4,000,000 worth of shares (1,000,000 units at $4.00)

      4 - MDxHealth SA (0001872529) (Issuer)

      2/28/23 4:22:02 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on MDxHealth SA with a new price target

      Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00

      10/31/24 8:59:17 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • TD Cowen initiated coverage on MDxHealth SA with a new price target

      TD Cowen initiated coverage of MDxHealth SA with a rating of Outperform and set a new price target of $7.00

      5/31/23 7:34:28 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • Oppenheimer resumed coverage on MDxHealth SA with a new price target

      Oppenheimer resumed coverage of MDxHealth SA with a rating of Outperform and set a new price target of $18.00

      7/18/22 9:23:47 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    SEC Filings

    See more
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      7/3/25 4:48:27 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      6/6/25 5:12:22 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      5/14/25 4:05:22 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Leadership Updates

    Live Leadership Updates

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors

                  Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chie

      7/8/24 8:00:00 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Resignation of Board Member

      Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensaert's resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Michael K. McGarrity, CEO of mdxhealth, commented: "On behalf of the Board of Directors and the employees of mdxhealth, I would like to thank Jan for his suppor

      2/16/24 8:45:00 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Financials

    Live finance-specific insights

    See more
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our perfo

      2/26/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      11/14/24 3:15:43 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MDxHealth SA

      SC 13D/A - MDxHealth SA (0001872529) (Subject)

      10/28/24 2:52:50 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      10/4/24 5:14:19 PM ET
      $MDXH
      Medical Specialities
      Health Care